Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Book Value per Share : NT$15.50 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Book Value per Share?

Great Novel Therapeutics Biotech & Medicals's book value per share for the quarter that ended in Dec. 2023 was NT$15.50.

During the past 12 months, Great Novel Therapeutics Biotech & Medicals's average Book Value Per Share Growth Rate was 43.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 33.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 27.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Great Novel Therapeutics Biotech & Medicals was 36.90% per year. The lowest was 14.10% per year. And the median was 33.90% per year.

Great Novel Therapeutics Biotech & Medicals's current price is NT$47.30. Its book value per share for the quarter that ended in Dec. 2023 was NT$15.50. Hence, today's PB Ratio of Great Novel Therapeutics Biotech & Medicals is 3.05.

During the past 6 years, the highest P/B Ratio of Great Novel Therapeutics Biotech & Medicals was 11.64. The lowest was 2.89. And the median was 5.35.

Good Sign:

Great Novel Therapeutics Biotech & Medicals stock PB Ratio (=3.14) is close to 3-year low of 2.89

Great Novel Therapeutics Biotech & Medicals Book Value per Share Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Book Value per Share Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Book Value per Share

Get a 7-Day Free Trial

4.19

6.46

7.83

10.77

15.50

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Book Value per Share	Get a 7-Day Free Trial					7.83	6.85	10.77	16.28	15.50

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Book Value per Share

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's PB Ratio falls into.

Great Novel Therapeutics Biotech & Medicals Book Value per Share Calculation

Great Novel Therapeutics Biotech & Medicals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(618.04	-	0.00)	/	39.88
	=	15.50

Great Novel Therapeutics Biotech & Medicals's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(618.04	-	0.00)	/	39.88
	=	15.50

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Great Novel Therapeutics Biotech & Medicals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines